Compile Data Set for Download or QSAR
maximum 50k data
Found 128 Enz. Inhib. hit(s) with all data for entry = 8531
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256239(US9487483, 91)
Affinity DataIC50:  6nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256272(US9487483, 124)
Affinity DataIC50:  10nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256259(US9487483, 111)
Affinity DataIC50:  10nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256178(US9487483, 30)
Affinity DataIC50:  10nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256246(US9487483, 98)
Affinity DataIC50:  11nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256269(US9487483, 121)
Affinity DataIC50:  15nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256170(US9487483, 22)
Affinity DataIC50:  15nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256171(US9487483, 23)
Affinity DataIC50:  16nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256265(US9487483, 117)
Affinity DataIC50:  16nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256254(US9487483, 106)
Affinity DataIC50:  18nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256208(US9487483, 60)
Affinity DataIC50:  22nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256263(US9487483, 115)
Affinity DataIC50:  22nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256153(US9487483, 5)
Affinity DataIC50:  22nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256210(US9487483, 62)
Affinity DataIC50:  24nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256187(US9487483, 37)
Affinity DataIC50:  24nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256212(US9487483, 64)
Affinity DataIC50:  24nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256243(US9487483, 95)
Affinity DataIC50:  25nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256174(US9487483, 26)
Affinity DataIC50:  26nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256177(US9487483, 29)
Affinity DataIC50:  28nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256173(US9487483, 25)
Affinity DataIC50:  28nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256257(US9487483, 109)
Affinity DataIC50:  28nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256197(US9487483, 49)
Affinity DataIC50:  29nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256221(US9487483, 73)
Affinity DataIC50:  29nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256209(US9487483, 61)
Affinity DataIC50:  32nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256236(US9487483, 88)
Affinity DataIC50:  34nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256251(US9487483, 103)
Affinity DataIC50:  36nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256204(US9487483, 56)
Affinity DataIC50:  37nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256213(US9487483, 65)
Affinity DataIC50:  38nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256230(US9487483, 82)
Affinity DataIC50:  38nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256229(US9487483, 81)
Affinity DataIC50:  39nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256175(US9487483, 27)
Affinity DataIC50:  40nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256206(US9487483, 58)
Affinity DataIC50:  41nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256219(US9487483, 71)
Affinity DataIC50:  41nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256207(US9487483, 59)
Affinity DataIC50:  43nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256258(US9487483, 110)
Affinity DataIC50:  48nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256211(US9487483, 63)
Affinity DataIC50:  49nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256231(US9487483, 83)
Affinity DataIC50:  50nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256154(US9487483, 6)
Affinity DataIC50:  56nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256202(US9487483, 54)
Affinity DataIC50:  57nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256234(US9487483, 86)
Affinity DataIC50:  58nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256232(US9487483, 84)
Affinity DataIC50:  60nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256180(US9487483, 32)
Affinity DataIC50:  63nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256275(US9487483, 127)
Affinity DataIC50:  80nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256184(US9487483, 39)
Affinity DataIC50:  85nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256261(US9487483, 113)
Affinity DataIC50:  90nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256244(US9487483, 96)
Affinity DataIC50:  90nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256195(US9487483, 47)
Affinity DataIC50:  91nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256241(US9487483, 93)
Affinity DataIC50:  92nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256238(US9487483, 90)
Affinity DataIC50:  95nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM256176(US9487483, 28)
Affinity DataIC50:  100nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 128 total ) | Next | Last >>
Jump to: